Compare PLAY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | XFOR |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | 23610 | 143 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.2M | 407.5M |
| IPO Year | 2011 | N/A |
| Metric | PLAY | XFOR |
|---|---|---|
| Price | $10.13 | $3.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $23.83 | $9.00 |
| AVG Volume (30 Days) | ★ 1.7M | 343.7K |
| Earning Date | 06-09-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.61 | $1.35 |
| 52 Week High | $35.38 | $4.83 |
| Indicator | PLAY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 38.17 |
| Support Level | $9.61 | $3.57 |
| Resistance Level | $15.29 | $4.09 |
| Average True Range (ATR) | 0.65 | 0.23 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 20.83 | 0.00 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.